Designing and Development of a Tandem Bivalent Nanobody against VEGF<sub>165</sub>

Farnaz Khodabakhsh 1, Morteza Salimian 2, Pardis Ziaee 3, Fatemeh Kazemi-Lomedasht 4, Mahdi Behdani 4, and Reza Ahangari Cohan 5

1. Department of Genetics and Advanced Medical Technology, Medical Biotechnology Research Center, Faculty of Medicine, AIA University of Medical Sciences, Tehran, Iran
2. Department of Medical Laboratory, Kashan University of Medical Sciences, Kashan, Iran
3. Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran
4. Venom and Biotherapeutics Molecules Laboratory, Department of Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
5. Department of Nanobiotechnology, New Technologies Research Group, Pasteur Institute of Iran, Tehran, Iran

Abstract

Background: Inhibition of angiogenesis using monoclonal antibodies is an effective strategy in cancer therapy. However, they could not penetrate sufficiently into solid tumors. Antibody fragments have solved this issue. However, they suffer from short in vivo half-life. In the current study, a tandem bivalent strategy was used to enhance the pharmacokinetic parameters of an anti-VEGF<sub>165</sub> nanobody.

Methods: Homology modeling and MD simulation were used to check the stability of protein. The cDNA was cloned into pHEN6C vector and the expression was investigated in WK6 Escherichia coli (E. coli) cells by SDS-PAGE and western blot. After purification, the size distribution of tandem bivalent nanobody was investigated by dynamic light scattering. Moreover, in vitro antiproliferative activity and pharmacokinetic study were studied in HUVECs and Balb/c mice, respectively.

Results: RMSD analysis revealed the tandem bivalent nanobody had good structural stability after 50 ns of simulation. A hinge region of llama IgG2 was used to fuse the domains. The expression was induced by 1 mM IPTG at 25 °C for overnight. A 30 kDa band in 12% polyacrylamide gel and nitrocellulose paper has confirmed the expression. The protein was successfully purified using metal affinity chromatography. MTT assay revealed there is no significant difference between the antiproliferative activity of tandem bivalent nanobody and the native protein. The hydrodynamic radius and terminal half-life of tandem bivalent nanobody increased approximately 2-fold by multivalency compared to the native protein.

Conclusion: Our data revealed that the physicochemical as well as in vivo pharmacokinetic parameters of tandem bivalent nanobody was significantly improved.

Keywords: Cancer, Pharmacokinetics, Single domain antibody, Vascular endothelial growth factor

Introduction

Approximately 30% of recombinant DNA technology based drugs are antibodies that are frequently used in inflammatory diseases and cancers. Monoclonal antibodies (mAbs) could concurrently be used for diagnostic and therapeutic purposes in medicine. However, their manufacturing is practically difficult and costly and puts an extra burden on healthcare system. In addition, because of the large size (~150 kDa), they have a poor distribution and low penetration rate into the solid tumors. Therefore, many efforts have been made to overcome such limitations and improve the pharmacological properties including design of antigen-binding fragments (Fab), variable fragments (Fv), single-chain variable Fragments (scFv), and single-domain antibodies (Nanobodies). Antibody fragments have superior advantages over conventional antibodies. For example, due to the smaller size, they penetrate easily to solid tissues. Moreover, the lack of Fc domain reduces the risk of immunogenicity in humans as well as heterogeneity in the product. In the
manufacturing process, they do not need mammalian expression systems which are often costly and time-consuming. Prokaryotic expression systems can be applied to manufacture them and usually provide much more protein than eukaryotic systems. Due to high solubility, low cost of production, high stability at harsh conditions, rapid penetration into solid tissues, detection of hidden antigenic sites, and lower immunogenicity with a specific affinity, the smallest binding antibody fragments (Nanobodies) have more advantages than other antibody fragments. However, they suffer from short in vivo half-life and low affinity. Numerous strategies were developed for enhancing pharmacokinetic parameters of small therapeutic proteins such as PEGylation and PASylation. However, each strategy has its own cons and pros. For example, PASylation technique suffers from low expression level of PASylated protein due to repeat sequences as observed in our previous study. Moreover, in another study, it was elucidated that the PAS sequence could decrease the affinity of PASylated protein in comparison to the native one. The preparation of multivalent forms of antibody fragments enhances the efficacy and in vivo distribution. Increasing the valency of antibody derivatives improves the pharmacokinetic properties of these fragments as well. In addition, by repeating monovalent single domain antibodies, the binding avidity could increase compared to the monomeric form.

Since Vascular Endothelial Growth Factor (VEGF) is a key factor in tumor angiogenesis and metastasis, therefore, in the current study, a tandem bivalent single-domain antibody against VEGF was designed, expressed, and purified. Finally, the size distribution and in vivo half-life of purified protein were investigated.

Materials and Methods

3D-modeling and molecular dynamics simulation

The 3D-structure of tandem bivalent nanobody was generated using homology modeling. The crystal structure of nanobody NbFedF9 (PDB code: 4W6Y, 1.57 Å) was used as the template. One hundred models were generated by Modeller software version 9.24. The best model was selected based on discrete optimized protein energy (DOPE) score. The quality of the model was assessed by phi (φ) and psi (ψ) analysis. The stability of tandem bivalent nanobody was finally investigated by all-atom molecular dynamics simulation using GROMACS package version 2016.3 with OPLS-AA forcefield in a Linux Mint 17 operating system. The Extended Simple Point Charge (SPCE) water model was used for the solvent molecules. Tandem bivalent nanobody was solvated in a cubic box at a distance of 1 nm from the edges. The periodic boundary conditions were also applied. Appropriate number of Na⁺ and Cl⁻ ions were added to neutralize the system. The steepest descent algorithm was used for energy minimization of the system within 200 picoseconds. The temperature and pressure of system were kept at 300 K and 1 atmosphere using Berendsen thermostat and Parrinello-Rahman barostat algorithms, respectively. The system was then subjected to the all-atom simulation until the Root Mean Square Deviation (RMSD) of the fusion protein reached to a plateau. All visualizations were performed using VMD software version 1.9.3.

Construct design and cloning

The anti-VEGF specific nanobody gene was a gift from Dr. Behdani (Pasteur Institute of Iran) and subcloned into pHEN6C vector. The nanobody gene was amplified using forward (5’-GCCCAG CCG GCC ATG GCC CAG KTG CAG CTA CAG GAG TCN GGN GG-3’) and reverse (5’-GCC TGA TTC CTG CAG CTG CAC CTG TGC CAT TGG AGC TTG GGG AGC TTT GGA GCT GGG TGC TTC GCT GTG GTG CGC TGA GGA GAC GGT GAC CTG GGT-3’) primers. The PCR program was as follows: initial denaturation at 95°C for 10 min, followed by 30 cycles of denaturation at 95°C for 40 s, annealing at 60°C for 40 s, extension at 72°C for 40 s, and final elongation at 72°C for 10 min. After the PCR purification, the product was digested with Psil and Sfi restriction enzymes and ligated into pHEN6C vector that comprises the first anti-VEGF nanobody. The accuracy of recombinant construct (VEGF-tandem bivalent nanobody) was confirmed by sequencing.

Expression

Transformation of the recombinant plasmid to E. coli cells was performed by heat shock method. The cells were cultured on Luria–Bertani (LB) agar plates with 100 μg/ml of ampicillin and incubated overnight at 37°C. The colonies were then inoculated into 5 ml of Terrific Broth (TB) medium in a shaker incubator at 37°C until the OD600 reached to 0.5. The expression was induced by adding 1 mM of Isopropyl β-D-1-thiogalactopyranoside (IPTG) to the culture after 16 hr. Finally, the cells were centrifuged at 4000 g for 5 min and the obtained pellets were stored at -20°C for further steps.

SDS-PAGE and western blotting

SDS–PAGE was done in a 12% (w/v) gel with a Bio-Rad instrument according to the manufacturer's protocol (Bio-Rad, USA). The protein samples were mixed with the loading buffer and boiled at 95°C for 5 min and subsequently subjected to electrophoresis. The staining of gel was done using Coomassie Brilliant Blue G-250. The gel was destained using 2.5% methanol and 10% acetic acid for 4 hr. To identify the desired protein, a western blot technique was employed using anti-His monoclonal antibody. The separated proteins were transferred onto a nitrocellulose membrane (Sigma, USA). Then, blocking step was performed using 2% skim milk in PBS. The specific detection of the desired protein was carried out by an
Designing and Development of a Tandem Bivalent Nanobody against VEGF<sub>165</sub>

anti-His HRP conjugated antibody (1:2000 dilution, Roche, USA). The color development for peroxidase activity was performed by DAB solution (60 mg of DAB, 100 µl of H<sub>2</sub>O<sub>2</sub>, 6 ml of methanol, and 50 ml of TBS up to 100 ml of ultra-pure water) (Sigma, USA).

**Protein extraction and purification**

For purification, the bacterial cultures were scaled up to 750 ml in a shaker incubator at 37°C. When the OD<sub>600</sub> of cultures reached to 0.5, the induction was done with 1 Mm of IPTG and they were incubated for 16 hr. After harvesting the cells, the periplasm proteins were extracted from the pellets by the osmotic method. The nickel-nitritotriacetic acid (Qiagen, USA) affinity chromatography was used for purification of the periplasmic extracts. The washing step was done using 20 mM of imidazole, and then, the desired protein was eluted with 500 mM of imidazole. The purified protein was also analyzed using 12% gel polyacrylamide electrophoresis. The protein was concentrated and buffer exchanged using Amicon<sup>®</sup> ultrafilter (MWCO 3 kDa, Millipore, USA) for further characterizations. Additionally, the native protein was expressed and purified as control with the same procedures in the current study.

**Size distribution measurements**

Size distributions of tandem bivalent anti-VEGF<sub>165</sub> nanobody and anti-VEGF<sub>165</sub> nanobody were measured using Zetasizer Nano ZS (Malvern, USA) at concentration of 0.3 mg/ml.

**Proliferation assay**

The antiproliferative effect of nanobody and tandem bivalent nanobody were studied using Zetasizer Nano ZS (Malvern, USA) at concentration of 0.3 mg/ml.

**Pharmacokinetic study**

Balb/c mice (18 g, n=18) were used for pharmacokinetic study. An intravenous dose (5 mg/kg) was injected to each mouse. Blood samples were collected at different time intervals (0, 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, and 6 hr). PBS was used as negative control. After plasma preparation, the protein concentration was measured by a home-made ELISA using anti-His monoclonal antibody as previously described. The terminal half-life (T<sub>1/2</sub>) and Clearance (CL) were determined using linear regression of the last three plasma concentrations.

**Results**

**3D-modeling and molecular dynamics simulation**

Homology modeling and molecular dynamics simulation were used to check the stability of three dimensional structure of tandem bivalent nanobody. The crystal structure of nanobody NbFedF9 with a sequence identity of 72.1% was used for homology modeling. Ramachandran plot analysis (Phi and psi torsion angles) elucidated that 96.8% of residues were located in favored and allowed regions in the generated 3D-model. The RMSD analysis revealed that the 3D-model of fusion protein was stable after ~20 nanoseconds of molecular dynamics simulation in water (Figure 1).

**Construct design and cloning**

The nanobody gene was amplified using the primers from pHEN6-anti-VEGF<sub>165</sub> nanobody plasmid. The PCR product was purified, digested with PstI and SfiI restriction enzymes, and ligated into pHEN6C expression vector to construct the tandem bivalent nanobody (Figure 2). DNA sequencing confirmed the accuracy of the nanobody (S1, supplementary file) and tandem bivalent nanobody (S2, supplementary file) constructs.

**SDS-PAGE and western blotting**

SDS-poly acrylamide gel electrophoresis showed a band at ~30 kDa in the 12% gel (Figure 3). The western blot also confirmed the expression of recombinant anti-VEGF<sub>165</sub> tandem bivalent nanobody (Figure 4).

**Protein extraction and purification**

The nanobody and bivalent nanobody were extracted from the periplasmic space by the osmotic method and subjected to nickel affinity chromatography. Both

![Figure 1](image-url)  
**Figure 1.** A) The root mean square deviations of tandem bivalent nanobody structure during 50 nanoseconds of molecular dynamics simulation. The fusion protein was reached to a plateau after ~20 nanoseconds of simulation in water. B) The 3D-structure of the designed tandem bivalent nanobody after 50 nanoseconds of molecular dynamics simulation.
proteins were successfully eluted using buffer containing 500 mM of imidazole. The bivalent protein showed a band at ~30 kDa in 12% SDS-PAGE gel (Figure 5). However, the native protein showed a band at ~15 kDa in the 12% SDS-PAGE gel (Figure 6). The proteins were finally concentrated and buffer exchanged.

Size distribution

The hydrodynamic radius of tandem bivalent anti-VEGF_{165} nanobody increased approximately 2-fold by multivalency compared to anti-VEGF_{165} nanobody (Figure 7). Size distribution showed a peak at 153 nm for tandem bivalent nanobody, while this value was 77 nm for anti-VEGF_{165} nanobody. Size distribution parameters of nanobody and tandem bivalent nanobody are summarized in table 1.

Proliferation assay

The antiproliferative activity of nanobody and tandem bivalent nanobody was studied on HUVEC and HEK293 cells. As expected, the proteins did not exhibit an anti-proliferative activity against HEK293 cells due to lack of VEGFR2 receptor on the surface cell (Data not shown). In contrast, both proteins inhibited the proliferation of HUVEC cells in a dose-dependent manner (Figure 8). Data analysis revealed that there was no significant difference between the antiproliferative activity of tandem bivalent nanobody and the native one.

Pharmacokinetic study

Pharmacokinetic study revealed that the terminal half-life (T_{1/2}) increased approximately 2-fold after a...
Designing and Development of a Tandem Bivalent Nanobody against VEGF₁₆₅

The single dose administration of the proteins (Figure 9). The measurement of pharmacokinetic parameters also elucidated that the extended in vivo half-life was obtained via a decline in the clearance of tandem bivalent nanobody (Table 2).

### Discussion

Cancer treatment using monoclonal antibodies is an ongoing practice. Monoclonal antibodies play inevitable roles in medicine and research. Most of them exert their effects by binding to transmembrane receptors or soluble ligands, interfering with signal transduction pathways, and thereby inhibiting tumor cell proliferation and angiogenesis. Because of low stability, solubility, and large size of conventional antibodies, next-generation antibodies have been developed. One approach is development of fragmented antibodies that just contain the antigen binding domain of whole antibodies. However, in some cases, such modifications remarkably affect both the function and affinity of native protein.

Development of single-domain antibodies with proper antigen-binding specificity is one of the most popular methods for fragmented antibody generation. There is a high sequence similarity between human variable...
Table 2. Pharmacokinetic parameters obtained for tandem bivalent nanobody and the native one

<table>
<thead>
<tr>
<th>Protein</th>
<th>$T_{1/2}$ (min)</th>
<th>Clearance (ml/min)</th>
<th>PK factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nanobody</td>
<td>48</td>
<td>0.007</td>
<td>1</td>
</tr>
<tr>
<td>Tandem bivalent nanobody</td>
<td>102</td>
<td>0.003</td>
<td>2.1</td>
</tr>
</tbody>
</table>

In vivo pharmacokinetic data also revealed that the extended terminal half-life was associated with a decrease in the clearance parameter. In a recent study, Sadeghi A et al designed a mono-specific anti-VEGF$_{165}$ bivalent nanobody with extended plasma half-life for treatment of pathologic vascularization 23. In another study, Behdani et al developed an anti-VEGF2 diabody that could potently inhibit the VEGFR2 receptor on the surface of cancer cells 24.

**Conclusion**

In conclusion, recent studies indicated that multivalency can improve poor characteristics of fragmented antibodies to generate novel and potent magic tools for cancer therapy.

**Acknowledgement**

The authors express their deep gratitude to all who provided support during this research.

**References**


